| 1.395 -0.085 (-5.74%) | 08-14 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.94 |
1-year : | 2.19 |
| Resists | First : | 1.66 |
Second : | 1.87 |
| Pivot price | 1.45 |
|||
| Supports | First : | 1.3 |
Second : | 1.08 |
| MAs | MA(5) : | 1.48 |
MA(20) : | 1.46 |
| MA(100) : | 2 |
MA(250) : | 3.17 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1  |
| %K %D | K(14,3) : | 47.4 |
D(3) : | 54.1 |
| RSI | RSI(14): 41.6 |
|||
| 52-week | High : | 8.34 | Low : | 1.3 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ACXP ] has closed above bottom band by 18.3%. Bollinger Bands are 82.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 71 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.4 - 1.41 | 1.41 - 1.42 |
| Low: | 1.29 - 1.3 | 1.3 - 1.31 |
| Close: | 1.38 - 1.39 | 1.39 - 1.41 |
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
Fri, 14 Aug 2026
ACXP: Advanced ibezapolstat program, secured funding, and expanded patent estate for CDI treatment - TradingView
Fri, 14 Aug 2026
ACXP: Cash position improved and ibezapolstat advanced toward pivotal trials, supported by new financing - TradingView
Fri, 14 Aug 2026
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update - Yahoo Finance Singapore
Fri, 14 Aug 2026
Acurx Receives Conditional FDA Acceptance for C. difficile Drug Name - Stock Titan
Thu, 13 Aug 2026
ACXP: Net loss narrowed, but cash runway is short; new funding is needed to sustain clinical progress - TradingView
Thu, 13 Aug 2026
Acurx Pharmaceuticals (ACXP) trims losses and raises $6.2M to fund antibiotic pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 4 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 5.6 (%) |
| Shares Short | 102 (K) |
| Shares Short P.Month | 108 (K) |
| EPS | -3.79 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.06 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -66.5 % |
| Return on Equity (ttm) | -160.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -0.37 |
| PEG Ratio | 0 |
| Price to Book value | 0.67 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.98 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|